Evidence map›Paper›PMID 42253939›Full record

ReviewMedComm2026

Epigenetic Regulation in Cardiovascular Diseases: Mechanisms and Therapeutic Targets.

Wangzheqi Zhang, Chenyang Mu, Rui Zhao, Runwei Ma, Xuehai Liu, Haoling Zhang, Zengwu Wang, Jing-Jing Zhang

Abstract readReview
In one paragraph

Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wangzheqi ZhangSchool of Anesthesiology Naval Medical University Shanghai China.
Chenyang MuDepartment of Nursing Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China.ORCID https://orcid.org/0000-0002-5376-0746
Rui ZhaoGansu University of Chinese Medicine Lanzhou Gansu Province China.
Runwei MaFuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University Kunming China.
Xuehai LiuClinical College of Traditional Chinese Medicine Gansu University of Chinese Medicine Lanzhou Gansu Province China.
Haoling ZhangDepartment of Biomedical Sciences, Advanced Medical and Dental Institute Universiti Sains Malaysia Penang Malaysia.
Zengwu WangDivision of Prevention and Community Health, National Center for Cardiovascular Disease, National Clinical Research Center of Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease Fuwai Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences Beijing China.
Jing-Jing ZhangFuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University Kunming China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) arise as the product of multiple factors, including genetic predisposition and environmental exposure, but the molecular and cellular interplays underlying such a pathogenetic process leading to sustained pathological conditions remain largely unknown. A growing body of evidence indicates that epigenetic mechanisms, including DNA methylation, histone modifications, chromatin remodeling, noncoding RNAs, and RNA modifications, are important for cardiovascular development, adaptation, and disease. However, findings from these studies are fragmented across different genomic contexts or disease-focused scenarios, lacking systematic integration for a global view connecting epigenetic dynamics to cardiovascular phenotypes and their clinical implications. An overall picture of epigenetic modulation in CVDs is therefore provided. Common epigenetic mechanisms are described in a cell type and disease stage-specific context, and the roles of environmental and lifestyle factors in remodeling the cardiovascular epigenome are illustrated. Novel epigenetic biomarkers and therapeutic interventions are also assessed. Emphasis is placed on epigenomic plasticity, enhancer focused control, and network-level reprogramming as key concepts that drive disease remodeling. By unifying mechanistic understanding with translational evidence, this review frames CVD as a disorder of stabilized regulatory states and defines avenues for precision epigenomic manipulation.

Indexed as

cardiovascular diseaseschromatin remodelingenhancer rewiringepigenetic regulationnoncoding RNAsprecision epigenetic therapy

Identifiers

PMID42253939
PMCPMC13240140

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.